For instance, dual CTLA-4 and PD-(L)1 blockade restores T cell responses in STK11-mutant tumours by reprogramming the myeloid compartment toward anti-tumour phenotypes and restoring anti-tumour efficacy [45]. The gene discussed is STK11; the disease is neoplasm.